Teva Pharmaceutical Industries Ltd. (TEVA)

Oncology Corporate Profile

Stock Performance

56.2300
0.7300

HQ Location

1090 Horsham Rd.
North Wales, PA 19454

Company Description

Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011.

Website: http://www.tevapharm.com/

Brand Generic Indication
Actiq®fentanyl citrateActiq® is an opioid analgesic indicated only for management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
Bendeka®bendamustine hydrochlorideBendeka® hydrochloride is an alkylating drug indicated for treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established; indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Fentora®fentanyl buccalFentora® is indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking around-the-clock medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid daily for a week or longer. This product must not be used in opioid non-tolerant patients because life-threatening hypoventilation and death could occur at any dose in patients not on a chronic regimen of opioids. For this reason, Fentora® is contraindicated in the management of acute or postoperative pain. Fentora® is intended to be used only in the care of opioid tolerant cancer patients and only by healthcare professionals who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.
Synribo®omacetaxine mepesuccinateSynribo® for Injection is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI). This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Synribo®.
Tevagrastim®tbo'filgrastimTevagrastim® is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy. Tevagrastim® is indicated for the mobilisation of peripheral blood progenitor cells (PBPC). In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of 0.5 x 109/l, and a history of severe or recurrent infections, long term administration of Tevagrastim® is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events. Tevagrastim® is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.
Treanda®bendamustine hydrochlorideTreanda® for Injection is an alkylating drug indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. Treanda® for Injection is indicated for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Trisenox®arsenic trioxideTrisenox® is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the translocation or PML/RAR-alpha gene expression.
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
custirsen / TV-1011 (OGX-011)clusterin inhibitor1st line metastatic castrate-resistant Prostate cancer (CRPC)IIIOncogenex
custirsen / TV-1011 (OGX-011)clusterin inhibitor1st line metastatic Non Small Cell Lung Cancer (NSCLC)IIIOncogenex
custirsen (+ cabazitaxel) / TV-1011 (OGX-011)clusterin inhibitor2nd line metastatic castrate-resistant prostate cancer (CRPC)IIIOncogenex
Unnamedpeg-GCSFSupportive CareIII
Rituxan® / rituximabanti-CD20 monoclonal antibodyNon-Hodgkin's Lymphoma (NHL)III
Treanda® / bendamustinealkylating agent1st line metastatic Non-Hodgkin's Lymphoma (NHL)III
Trisenox® / arsenic trioxidetaxane (a synthetic retinoid)Acute Myelogenous Leukemia (AML)III
lestaurtinib / CEP-701Flt-3 kinase inhibitorAcute Myelogenous Leukemia (AML)II
tamibarotene (+ arsenic trioxide) / INNO-507RAR alpha/beta agonistAcute Promyelocytic Leukemia (APL)IICytRx
CEP-32496BRAF kinase inhibitorBreast cancerII
obatoclax / CEP-41601pan-inhibitor of Bcl-2 proteinsFollicular Non-Hodgkin's Lymphoma (f-NHL)II
obatoclax / CEP-41601pan-inhibitor of Bcl-2 proteinsHodgkin's LymphomaII
obatoclax / CEP-41601pan-inhibitor of Bcl-2 proteinsMyelodysplastic Syndrome (MDS)II
obatoclax / CEP-41601pan-inhibitor of Bcl-2 proteinsMyelofibrosisII
lestaurtinib / CEP-701Flt-3 kinase inhibitorMyeloproliferative disordersII
tamibarotene / INNO-507RAR alpha/beta agonistNon Small Cell Lung Cancer (NSCLC)IICytRx
CEP-9722PARP inhibitorNon Small Cell Lung Cancer (NSCLC)II
CT-011PD-1 inhibitorVarious cancer typesIICuretech Ltd.
Quinamed® / amonafide dihydrochloridetopoisomerase II inhibitorBreast cancerII
Quinamed® / amonafide dihydrochloridetopoisomerase II inhibitorOvarian cancerII
Quinamed® / amonafide dihydrochloridetopoisomerase II inhibitorProstate cancerII
Synribo® / omacetaxine mepesuccinateprotein synthesis inhibitorAcute Myelogenous Leukemia (AML)II
Synribo® / omacetaxine mepesuccinateprotein synthesis inhibitorMyelodysplastic Syndrome (MDS)II
Treanda® (+ Rituxan®) / bendamustinealkylating agentMantle Cell Lymphoma (MCL)II
obatoclax / CEP-41601pan-inhibitor of Bcl-2 proteins1st line metastatic Small Cell Lung Cancer (SCLC)I
obatoclax / CEP-41601pan-inhibitor of Bcl-2 proteinsAcute Myelogenous Leukemia (AML)I
obatoclax / CEP-41601pan-inhibitor of Bcl-2 proteinsMantle Cell Lymphoma (MCL)I
CEP-18770proteasome inhibitorMultiple MyelomaI
obatoclax / CEP-41601pan-inhibitor of Bcl-2 proteinsMyelodysplastic Syndrome (MDS)I
CEP-9722PARP inhibitorVarious cancer typesI
CEP-11981VEGF-R/Tie-2 kinase inhibitorVarious cancer typesI
CEP-37440ALK/FAK kinase inhibitorVarious cancer typesI
Treanda® (+ Velcade®) / bendamustinealkylating agentMultiple MyelomaI
CXS-299cell cycle inhibitorVarious cancer typesPreclinical
CEP-32496B-RAF kinase inhibitorVarious cancer typesPreclinicalChampions Biotechnology

View additional information on product candidates here »

Source: http://www.tevapharm.com/

Recent News Headlines

5/22/2017 12:19 pm

5/22/2017 12:19 pm

5/22/2017 12:19 pm

5/22/2017 12:19 pm

5/22/2017 12:19 pm

5/22/2017 06:19 am

5/22/2017 06:19 am

5/22/2017 06:19 am

5/22/2017 06:19 am

5/22/2017 06:19 am

5/22/2017 12:19 am

5/22/2017 12:19 am

5/22/2017 12:19 am

5/18/2017 12:19 pm

5/18/2017 06:19 am

5/18/2017 12:19 am

5/18/2017 12:19 am

5/18/2017 12:19 am

5/18/2017 12:19 am

5/18/2017 12:19 am

5/17/2017 06:19 am

5/16/2017 06:19 am

5/15/2017 12:19 pm

5/15/2017 06:19 am

5/12/2017 12:19 pm